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Background: Genetic testing of the cystic ﬁbrosis transmembrane conductance (CFTR) gene is currently performed in patients with congenital bi-
lateral absence of vas deferens (CBAVD). This study was conducted to investigate the role of mutations in the CFTR gene in CBAVD-dependent
male infertility.
Methods: 73 Chinese patients diagnosed with CBAVD were studied. The entire coding regions and splice sites of 27 exons of the CFTR gene were
sequenced in 146 chromosomes from the 73 CBAVD patients. Screening was carried out using PCR, gel electrophoresis and DNA sequencing to
identify novel variants of the entire coding regions and boundaries of the 27 exons.
Results: Five novel nonsynonymous mutations, three novel splice site mutations and one deletion were identiﬁed by sequencing. Apart from the novel
variants, we also found 19 previously reported mutations and polymorphism sites. Thirty-four patients (46.57%) had the 5T variant (6 homozygous and
28 heterozygous) and in two of them it was not associated with any detectable mutation of the CFTR gene. All potential pathogenic mutations are not
contained in the 1000 Genome Project database. In total, the present study identiﬁed 30 potential pathogenic variations in the CFTR gene, 9 of which
had not previously been described.
Conclusions: Most patients with CBAVD have mutations in the CFTR gene. A mild genotype with one or two mild or variable mutations was
observed in all the patients. These ﬁndings improve our understanding of the distribution of CFTR alleles in CBAVD patients and will facilitate
the development of more sensitive CFTR mutation screening.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis transmembrane conductance regulator (CFTR); Congenital bilateral absence of vas deferens (CBAVD); Sequencing; Mutation⁎ Corresponding author.
⁎⁎ Correspondence to: X. Ma, Center for Genetics, National Research Institute
for Family Planning, 12, Dahuisi Road, Haidian, Beijing 100081, China. Tel.: +86
10 62176870; fax: +86 10 62179151.
⁎⁎⁎ Correspondence to: B. Wang, Center for Genetics, National Research
Institute for Family Planning, 12, Dahuisi Road, Haidian, Beijing 100081, China.
Tel.: +86 10 62173443.
E-mail addresses: genetic@263.net.cn (X. Ma), wbbahu@163.com
(B. Wang).
1 These authors contributed equally to the work.
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2012.01.0051. Introduction
Congenital bilateral absence of the vas deferens (CBAVD)
[MIM #277180] is an autosomal recessive disease and occurs
in 1–2% of infertile men [1]. Male infertility as a result of
CBAVD is a recognized primary genital form of cystic fibrosis
(CF) [MIM #219700]. CF is a common severe disease in Cau-
casians populations, but is very rare in Asian populations [2–4].
About 2–6% of male infertility is caused by the mutations inby Elsevier B.V. All rights reserved.
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or ABCC7) [MIM #602421] gene [5]. Over 1500 CF-causing
CFTR mutations have been identified (Cystic Fibrosis Mutation
Database, 2007). The majority of adult males with CF have
CBAVD. The first CFTR mutation in CBAVD patients was
identified in 1990 [6]. However, it has been shown that muta-
tions in the CFTR gene are present in 85% of men with CF
where CBAVD is not associated with renal malformations [7].
CBAVD patients typically carry one or more mutation of the
gene. About 35% of Iranian males with CBAVD have a single
detectable CFTR mutation or polymorphism, about 40% have 2
mutations (common CFTR mutations or IVS8-5T polymor-
phism) [8]. The most common CFTR gene mutation in many
populations is a deletion named ΔF508, resulting in the loss
of the amino acid phenylalanine in the mature CFTR protein
[9–11]. The 5T variant in the polymidine tract of intron
8 (IVS8-5T) is common in the general population of many
countries, but a higher than normal frequency of this allele
has been found in CBAVD patients [12]. About 27% of pa-
tients with CBAVD from the Croatian population had the poly-
thymidine variant 5T found at the polymorphic Tn locus in
intron 8 of the CFTR gene. The 5T polymorphism can be
found in combination with a TG11, TG12, or TG13 allele
[13–15]. The skipping of exon 9 is regulated by the polythymi-
dine tract in intron 8 [16]. It has been shown that the clinical
symptoms and their severity are correlated with the level of ab-
normal CFTR transcripts [17,18]. A TG repeat, located up-
stream of the polymidine tract, could modulate the effect of
the 5T [15,19,20].
The CFTR gene contains 27 exons encompassing 180 kb of
DNA on chromosome 7q31.2. The CFTR protein is a glycosy-
lated transmembrane protein, which functions as a chloride
channel. It regulates the outwardly rectifying chloride channel
[21], it inhibits the amiloride sensitive epithelial sodium chan-
nel [22], and it influences extracellular ATP delivery [23] and
HCO3 transport [24]. The detection of CFTR mRNA in
human fetuses suggests that CFTR plays an important role in
the early development of the reproductive tissues [25]. Apart
from its chloride channel function it also functions as a regula-
tor to interact with other proteins. CFTR is expressed in epithe-
lial cells of exocrine tissues, such as the pancreas, sweat glands,
lungs, and vas deferens [21]. While CFTR is expressed
throughout the body, CFTR abnormalities predominantly im-
pact the pulmonary, digestive, and male reproductive systems,
as well as the sinuses and sweat glands [26].
Mutations in the CFTR are common in men with CBAVD
and it has been suggested that this syndrome represents a
mild form of CF. We hypothesized that men with CBAVD
also have mutations in the CFTR which, in addition to causing
infertility may lead to subclinical bacterial pulmonary infection
and inflammation consistent with mild CF [27,28]. In contrast
to CF patients, when CFTR is involved, at least one of the mu-
tant CFTR genes of CBAVD patients harbors a mild mutation
[29–31].
It has been shown that 30%–40% of the chromosomes of
males with CBAVD carry a splice variant, the 5T allele, in
the site of intron 8 [12]. The studies vary in their methods fordetecting mutations in the CFTR gene, and include restriction-
enzyme based methods, use of specific primers, semi-
quantitative fluorescent multiplex PCR (QFM-PCR), temporal
temperature gradient gel electrophoresis (TTGE) and sequenc-
ing. In our study, 27 sets of oligonucleotide primers were
designed to amplify and sequence the individual exons and
the immediate flanking sequences in the introns for detection
of CFTR gene mutations.
2. Materials and methods
2.1. Samples
We investigated a total of 73 male patients with azoospermia
and congenital bilateral absence of vas deferens from the Uro-
logical Department, Peking Union Medical College Hospital,
Chinese Academy of Medical Science, Beijing, China, during
the period 2005–2010. The patients were between 21 and
44 years old. They were all given a complete physical examina-
tion by the same physician, with particular attention to the tes-
tes, vasa deferentia, epididymides, and prostate gland. The
diagnosis of CBAVD was initially suggested by impalpable
scrotal vas on physical examination and ultrasonography, sub-
sequently confirmed by cytobiochemical characteristics, name-
ly azoospermia with low semen volume (b2.0 mL) and
decrease of fructose and carnitine concentrations, followed by
hormonal analysis according to World Health Organization cri-
teria (1999). None of the patients had any of the classic symp-
toms of CF. Informed consent for the studies had been obtained
from the patients at the time of referral to the laboratory. The
clinical variables are listed in Table 1.
2.2. CFTR mutation scanning
Genomic DNA was extracted from peripheral blood leu-
kocytes using a commercial DNA isolation kit (Qiagen, Hil-
den, Germany). The 27 coding regions of the CFTR gene
were amplified by polymerase chain reaction (PCR) using
primers shown (Table 2). PCR products were sequenced on
an ABI 3730XL automated sequencer (Applied Biosystems,
Foster City, CA) for mutation analysis. Sequencing results
were compared with the wild-type CFTR gene sequence pub-
lished in the Human Gene Mutation Database (http://www.
hgmd.cf.ac.uk/ac/all.php). The CLC DNA workbench 5 sys-
tem was used to analyze the conversion of the CFTR protein
sequence.
3. Results
A total of 30 mutations were identified in 77 of the 146 al-
leles, as listed in Table 3.
Twenty-two of the 30 mutations were found only once.
Among the mutations identified, the 5T variant was the most
common, accounting for 20.5% of CBAVD alleles (30/146).
ΔF508 and R117H are the most common CBAVD mutations
in Northern European population, but none of these was
found in this study.
Table 1











1 29 N BHy 1.1 7.4
2 25 N BHy 0.5 6.4 Neg
3 28 BHy 0.5 6.4 Neg
4 33 N BHy 0.1 7 Pos
5 44 N BHy 0.7 7.4 Neg
6 37 N BHy 0.9 6.7 Neg
7 35 BHy 0.7 6.4 Neg
8 30 N BHy 0.8 6.4 Neg
9 32 BHy 1.6 6.4 Neg
10 27 N BHy 0.8 7 Neg
11 30 BHy 1 6.5 Neg
12 39 BHy 1.7 6.4 Neg
13 28 0.3 6.4 Neg
14 23 N 0.5 6.4 Neg
15 28 0.5 6.4 Neg
16 30 LA+RHy ICSI
17 21 N BHy 1 6.4 Neg
18 32 N BHy 0.3 6.7 Neg
19 32 N BHy 0.5 6.4 Neg
20 27 N BHy 1 6.4 Neg
21 24 N BHy 1.5 6.4 Neg
22 33 BHy 1 6.4 Neg
23 26 N BHy 0.7 6.4 Neg MESA
24 28 N BHy 1 6.4 Neg
25 28 N N 0.5 6.4 Neg
26 25 N BHy 0.8 6
27 40 N BHy 0.1 6.4
28 32 N BHy 0.6 7.4
29 26 BHy 0.4 6.4 Neg
30 34 N RA Neg
31 31 N BHy 1 6.4 Neg
32 35 Hy 0.2 6.4 Neg
33 30 BHy 1.5 6.4 Neg
34 26 N BHy 0.1 6.4
35 35 N 0.5 6.4 Neg
36
37 25 N BHy 1 6.4 Neg
38 34 BHy 1 6.4 Neg
39 32 N BHy 6
40 28 N RA+LA 0.4 6
41 35 N BHy 0.2 6.4 Neg
42 28 N LA
43 30 N BHy 1.8 6.5 Neg
44 31 N BHy 0.8 5.5
45 26 N BHy 0.5 7
46 28 N BHy 0.2 6.7 Pos
47 32 N BHy ﹤1 7.7 Neg MESA
48 24 N BHy 0.2 6.4 Neg
49 24 N BHy
50 25 N BHy 0.2 6.7 Pos
51 27 N BHy 0.2 6.4
52 24 BHy 0.5
53 27 BHy 1 6.4 Neg
54 33 N BHy 0.5 6 Neg
55 22 N 0.5 6.4 Neg
56 30 N BHy 0.2 6.7 Neg
57 39 N BHy 0.1 6 Neg
58 25 N BHy
59 26 N BHy 0.5 6.4 Neg
60 28 N BHy 0.1 6 Neg












62 43 N BHy 1 6.4 Neg
63 31 N BHy 0.5 7 Neg
64 26 N BHy 2 6.5 Neg
65 27 2 6.4 Neg
66 30 N BHy 1 6.4 Neg
67 28 N BHy 0.3 7 Neg
68 27 N BHy 0.4 6 Neg
69 26 N 0.2 Neg
70 28 N BHy 1
71 26 N BHy 0.05 6.4 Neg
72 27 N BHy 0.2 6.4 Neg
73
Pos, positive; Neg, negative; N, normal; B, bilateral; R, right; L, left; Hy, hypo-
plasia; A, aplasia; ART, assisted reproductive technology; MESA, microscopic
epididymal sperm aspiration; ICSI, intracytoplasmic single sperm injection.
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among the identified mutations. First, 5 novel heterozygous mis-
sense mutations were detected (Table 4). None of these mutations
was found among the general population and the mutations ob-
served in CFTR gene are all conserved in many species (Homo sa-
piens, Rattus norvegicus, Mus musculus, Oryctolagus cuniculus)
except for the mutation T338K (Fig. 1). Second, three novel splice
site mutations (870−1 G–C, 1209+1 G–C, and 1209+2 T–G)
were identified. Furthermore, one novel deletion (3635delT) was
detected (Supplement Fig. 1). Lastly, we have observed previously
reported mutations and polymorphisms (p.E217G, p.R347H,
p.V470M, p.R553X, p.I556V, p.T854T, p.G970D, p.P1290P,
p.Q1352H, p.Q1643Q, 744-5delGATT, IVS8-T5) (Supplementary
Table 1). All potential pathogenic mutations have not been previ-
ously reported in the NCBI dbSNP and are not contained in the
1000Genome Project database (http://browser.1000genomes.org/).
On screening of the poly T alleles in intron 8, six of the 73
CBAVD patients were shown to be homozygous for the 5T/
5T genotype, twenty-eight were heterozygous for the 5T/7T ge-
notype, thirty-seven were homozygous for the 7T/7T genotype
and two were heterozygous for the 7T/9T genotype. The fre-
quency of 5T alleles was 34.2%.
There was one patient homozygous for the missense muta-
tion (I556V/I556V), but most other patients carried a missense
or splicing mutation on at least one allele. Although a few mu-
tations are not classic CF mutations, we cannot exclude the pos-
sibility that they may contribute to a CBAVD phenotype.
In summary, this study led to the identification of 30 CFTR
gene mutations and presumably pathogenic alterations on 52.7%
of chromosomes from the 73 Chinese CBAVD patients. No muta-
tions in the regions sequenced were found in 29 patients (39.7%).
4. Discussions
For couples seeking genetic testing before assisted reproduc-
tion if the male infertility is caused by obstructive azoospermia,
Table 2
Primers for CFTR in PCR and sequencing.
Ampliﬁcation site PCR primer Product length Sequencing primer
CFTR-Exon 1 Forward: 5′-AGGTCTTTGGCATTAGGA-3′ 394 bp 5′-AGGTCTTTGGCATTAGGA-3′
Reverse: 5′-AAACAAGTGCATAGTAGCG-3′
CFTR-Exon 2 Forward: 5′-GCTGCTATGGAGTGAGGAGACA-3′ 909 bp 5′-TGTAAGAGATGAAGCCTGGT-3′
Reverse: 5′-CCTGGTCTCAAGCAATCCTCTC-3′
CFTR-Exon 3 Forward: 5′-TCTGGCTGAGTGTTTGGTGTTG-3′ 504 bp 5′-GTGGTTTCTTAGTGTTTGGAGT-3′
Reverse: 5′-TTGCTGAGCCCATTGAGATTG-3′
CFTR-Exon 4 Forward: 5′-TAAACTTGTCTCCCACTG-3′ 538 bp 5′-TAAACTTGTCTCCCACTG-3′
Reverse: 5′-TCAGCATTTATCCCTTA-3′
CFTR-Exon 5 Forward: 5′-ACTCCCGCACAATATCAATGG-3′ 597 bp 5′-AAACATTTATGAACCTGAGAAG-3′
Reverse: 5′-TGCCTTTGAGTTGGGTGGTTC-3′
CFTR-Exon 6a Forward: 5′-AAACAGCATTGGACCCACAGC-3′ 912 bp 5′-AGAACCACGAAGTGTTTGAT-3′
Reverse: 5′-TGCGCCTCTAATCCCAGCTAC-3′
CFTR-Exon 6b Forward: 5′-ATACCCACCGCTCATAG-3′ 578 bp 5′-CATAGGAGGCATTTACCAA-3′
Reverse: 5′-TAACACCCTGGACCAAC-3′
CFTR-Exon 7 Forward: 5′-TGCCCAAGGTCACACAGGTC-3′ 890 bp 5′-TGCCCAAGGTCACACAGGTC-3′
Reverse: 5′-CATTTGCAACCTCTGGCCTAG-3′
CFTR-Exon 8 Forward: 5′-TGAATCCTAGTGCTTGGCAA-3′ 359 bp 5′-ATAAGATGTAGCACAATGAGAGT-3′
Reverse: 5′-TCGCCATTAGGATGAAATCC-3′
CFTR-Exon 9 Forward: 5′-GCCATGTGCTTTTCAAACTAAT-3′ 352 bp 5′-AAAAAGAGACATGGACACCAAA-3′
Reverse: 5′-AAAAAGAGACATGGACACCAAA-3′
CFTR-Exon 10 Forward: 5′-GAATCCTGAGCGTGATTTGA-3′ 384 bp 5′-GATCCATTCACAGTAGCTTACCC-3′
Reverse: 5′-GATCCATTCACAGTAGCTTACCC-3′
CFTR-Exon 11 Forward: 5′-GCTGAGGATGGACGAGGAAGA-3′ 890 bp 5′-AAAATGGACCTATGGATGAT-3′
Reverse: 5′-CACCAAGATACGGGCACAGATT-3′
CFTR-Exon 12 Forward: 5′-AAACCCAACATCTTCAA-3′ 666 bp 5′-CATTCTGCCATACCAAC-3′
Reverse: 5′-CATTCTGCCATACCAAC-3′
CFTR-Exon 13 Forward: 5′-TGCTAAAATACGAGACATATTGCA-3′ 906 bp 5′-AGACCTTACACCGTTTCTCATT-3′
5′-GCCATTCATTTGTAAGGGAGT-3′Reverse: 5′-TACACCTTATCCTAATCCTATGAT-3′
CFTR-Exon 14a Forward: 5′-GGAGCCCTTCTTTGTGATTCAT-3′ 1551 bp 5′-ATTCTGGCTATAGAATGACATCA-3′
Reverse: 5′-CCCACCTCAGCCTCCTTAGTTA-3′
CFTR-Exon 14b+15 Forward: 5′-GGCATGGGAGGAATAGGTGAAG-3′ 1141 bp 5′-TGCGTCAGCCTGTGGAG-3′
5′-GTAGCCACCGCACTCCA-3′Reverse: 5′-GAGGTTCAACAAAGGGCACATG-3′
CFTR-Exon 16 Forward: 5′-GGGTTTCGGTAGAGGTA-3′ 947 bp 5′-TGAGGCTAGTTTCAAGTGTA-3′
Reverse: 5′-TGAGGCTAGTTTCAAGTGTA-3′
CFTR-Exon 17a Forward: 5′-CACCGCATATTCTCACT-3′ 838 bp 5′-TAGCAGCACTATCCTTGT-3′
Reverse: 5′-TAGCAGCACTATCCTTGT-3′
CFTR-Exon 17b Forward: 5′-GGAGCTGCCATTTCGTGTG-3′ 1110 bp 5′-ATTAGCCAGAAAACTCCCAG-3′
Reverse: 5′-GCTAGGACCCTTCACCAATATG-3′
CFTR-Exon 18 Forward: 5′-TGTGCCCTAGGAGAAGTGTGAA-3′ 807 bp 5′-GAATCCTATGACCCAGCAAT-3′
Reverse: 5′-AGCCAAGCCACTGACTGAGG-3′
CFTR-Exon 19 Forward: 5′-GCCCGACAAATAACCAAGTGAC-3′ 455 bp 5′-GCCCGACAAATAACCAAGTGAC-3′
Reverse: 5′-TGCTAACACATTGCTTCAGGCT-3′
CFTR-Exon 20 Forward: 5′-TGTTTATGGCATGGTAC-3′ 534 bp 5′-TGTTTATGGCATGGTAC-3′
Reverse: 5′-ATTGCTAACTTGGAGGT-3′
CFTR-Exon 21 Forward: 5′-CACAAGGGACTCCAAAT-3′ 837 bp 5′-CAGTTAGGGGTAGGTCCAGT-3′
Reverse: 5′-ACAGCAAGAAAGCACCA-3′
CFTR-Exon 22 Forward: 5′-TGGCAGGTAGTGGGGGTAGA-3′ 407 bp 5′-TGGCAGGTAGTGGGGGTAGA-3′
Reverse: 5′-CACGCAGACATGACAGCCTAAT-3′
CFTR-Exon 23 Forward: 5′-CCCATGGTTGAAAAGCTGATTG-3′ 465 bp 5′-CCCATGGTTGAAAAGCTGATTG-3′
Reverse: 5′-ACCTCACCACATGGCTCAGATC-3′
CFTR-Exon 24 Forward: 5′-GCTCTGGACATTGCATTCTTTG-3′ 800 bp 5′-GCTCTGGACATTGCATTCTTTG-3′
Reverse: 5′-TGGGGAGAGGAGAGAAAAAGG-3′
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cedure. However, the spectrum and frequency distribution of
CFTR gene mutations in most patients of European descent or
other countries may not be the same for all countries or ethnic-
ities. Therefore, it is important to clearly define the relevant
mutation parameters in the Chinese population.
The large cohort of patients studied in this work can help to
identify the frequency and significance of CFTR mutations
when screening these patients. The CFTR gene, encoded a1480-amino acid protein, acts as a cyclic adenosine monopho-
sphate (cAMP)-regulated chloride channel in the apical mem-
brane of epithelial cells. The CFTR protein is composed of
two repeated regions; each containing a transmembrane domain
(TMD1 or TMD2) and two putative nucleotide-binding folds
(NBF1 and NBF2). The two parts are linked by a cytoplasmic
hydrophilic regulatory (R) domain, which is required for pro-
tein kinase A sensitivity of channel gating [32,33]. Depending
on the effect at the protein level, CFTR mutations can be
Table 3
CFTR genotypes in 73 patients with congenital bilateral absence of the vas
deferens.
△F508 R117H Mutation genotypes IVS8-Tn n (%)
Two mutations detected
Neg Neg I556V/I556V 7T/7T 1(1.3)
Neg Neg I556V/1209+2 G–C 5T/7T 1(1.3)
Neg Neg I556V/726delATT 5T/5T 1(1.3)
Neg Neg I556V/− 5T/5T 1(1.3)
Neg Neg I556V/− 5T/7T 1(1.3)
Neg Neg G970D/− 5T/7T 1(1.3)
Neg Neg C592F/− 5T/5T 1(1.3)
Neg Neg 1209+1 G–C/− 5T/7T 1(1.3)
Neg Neg R553X/− 5T/7T 1(1.3)
Neg Neg Q1352H/− 5T/7T 1(1.3)
Neg Neg S485C/− 5T/7T 1(1.3)
Neg Neg A357T/− 5T/7T 1(1.3)
Neg Neg E217G/− 5T/7T 1(1.3)
Neg Neg R347H/− 5T/7T 1(1.3)
Neg Neg G451K/− 5T/7T 1(1.3)
Neg Neg L558S/− 5T/7T 1(1.3)
Neg Neg 3635delT/Q1352H 7T/7T 1(1.3)
Neg Neg A1136T/G970D 7T/7T 1(1.3)
Neg Neg 870−1 G–C/− 5T/7T 1(1.3)
Neg Neg 520−2 A-G/− 5T/7T 1(1.3)
Neg Neg R419I/− 5T/7T 1(1.3)
Neg Neg C491F/Q1643Q 7T/7T 1(1.3)
Neg Neg Q1352H/− 5T/7T 1(1.3)
Neg Neg R851X/− 5T/7T 1(1.3)
Neg Neg P750L/G970D 7T/7T 1(1.3)
One mutation detected
Neg Neg −/− 5T/7T 2(2.7)
Neg Neg −/− 5T/7T 3(4.1)
Neg Neg −/− 5T/7T 5(6.8)
Neg Neg −/− 5T/5T 2(2.7)
Neg Neg −/− 5T/5T 1(1.3)
Neg Neg G970D/− 7T/7T 2(2.7)
Neg Neg D993Y/− 7T/7T 1(1.3)
Neg Neg I556V/− 7T/7T 1(1.3)
Neg Neg T388R/− 7T/7T 1(1.3)
No mutation detected
Neg Neg −/− 7T/7T 8(10.9)
Neg Neg −/− 7T/7T 15(20.5)
Neg Neg −/− 7T/9T 2(2.7)
Neg Neg −/− 7T/7T 4(5.5)
Neg: Negative.
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CFTR synthesis because of mutations affecting splice sites
and nonsense mutations resulting in truncated CFTR protein,Table 4
The novel mutations found in the present study.
Mutation Location Nucleotide change Codon change
A357T Exon8 G–A at 1069 Ala-Thr
T388K Exon9 C–A at 1163 Thr-Lys
R419I Exon10 G–T at 1256 Arg-Ile
G451K Exon10 G–A at 1351 Gly-Lys
C592F Exon14 G–T at 1775 Cys-Phe
870−1 G–C Intron7 Splice error –
1209+1 G–C Intron8 Splice error –
1209+2 T–G Intron8 Splice error –
3635delT Exon22 Frameshift –which is mostly unstable and therefore degraded, and in muta-
tions shifting the coding frame in the gene (frameshift deletions
and insertions). Class II mutations, which was include the most
common mutation ΔF508, result in CFTR proteins that fail to
mature and are degraded. Class III mutations resulted in
CFTR proteins that mature and therefore reach the apical mem-
brane of the cell but exert abnormal regulatory properties on the
chloride channel. Class IV mutations result in CFTR channels
with abnormal conductive properties because of mutations in
the conductivity pore. Finally, Class V mutations result in
some functional CFTR proteins. Class I, II, and III mutations
are severe mutations, while class IV and V mutations are
known as mild mutations [34,35].
In the present study, nine mutations were described for the
first time: p.A357T, p.T388K, p.R419I, p.G451K, p.C592F,
870−1 G–C, 1209+1 G–C, 1209+2 T–G, 3635delT. They
were all found in the heterozygous state (Table 3). The muta-
tions (p.T388K, p.R419I, p.G451K) are located in the NBF1
domain, which contains a number of highly conserved motifs
predicted to bind and hydrolyse ATP. An exon 16 mis-sense
mutation in TMD-M9, p.D993Y [36], and an exon 18 mis-
sense mutation in TMD-M12 p.A1136T [37], two previously
described mutations were found in two CBAVD phenotypes.
Because the mutations are in highly conserved regions, the
changes in the amino acid in the transmembrane domain of
CFTR may cause defective channel formation in the resulting
protein (Fig. 2).
The CFTR mutation p.I556V has been reported in the pro-
ject of 1000 Genomes, and identified in Japanese infertility pa-
tients and French patients with asthma-like bronchopathy and
chronic diarrhea [38,39]. However, our study detected an
I556V gene mutation on both alleles in one Chinese CBAVD
patient; this was located in the domain which functions as the
ATP-binding domain. We suggest that this could be a
CBAVD-causing mutation.
In the majority of cases, CBAVD can be considered a genital
form of CF, presenting without the other clinical features of the
disease. There is a core of 25 most common mutations desig-
nated by the CF Steering Committee in 2001, which occur in
European populations with a frequency of ≥0.1%. Some muta-
tions are clearly associated with a mild phenotype [40]. Other
attempts to link mutations in CFTR to disease severity have
failed, suggesting an influence of non-CFTR gene modifiers
and environmental factors [2,41]. A large number of CF muta-
tions have been discovered during the past years, and undoubt-
edly, mutations often combine to cause disease. The most
common mutation in almost all CF populations is a deletion
of 3 base pairs named ΔF508, resulting in the loss of the
amino acid phenylalanine at position 508 in the mature CFTR
protein [9,10]. The CFTR genotype may contribute to the fre-
quency and severity of Wolffian duct malformations in
CBAVD patients [42].
IVS8-5T and ΔF508 were found to be common in Iranian
CBAVD patients. The frequency of IVS8-5T in the Iranian pa-
tients was similar to data published for Portuguese (27.4%) [43]
and Taiwanese (29.2%) [44] patients, but higher than that in
Turkish patients (19.6%) [45]. Approximately 27% of patients
Fig. 1. The conserved analysis in species.
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dine variant 5T [46]. In our study, the frequency of 5T polymor-
phism is 37.5%. The length of the polythymidine tract in intron
8 (IVS8-Tn polymorphism) of the CFTR gene affects the splicing
efficiency of intron 8. Three alleles have been identified in IVS8
(9T, 7T and 5T). The 9T allele is associated with the most effi-
cient usage of the intron 8 splice acceptor site and allows normal
reading of the gene. Genetic studies have shown that the IVS8-5T
variant causes alternative splicing of exon 9 increasing the pro-
portion of CFTR transcripts that lack exon 9 whose translation
products will not contribute to apical chloride channel activity.
When 5Twas founded in compound heterozygosity with a severe
CFTR mutation (or 5T), it may accompanied by pathology. The
5T polymorphism was therefore classified as a disease mutation
with partial penetrance [47]. Genetic studies have found that a
polymorphic polythymidine (Tn) locus located within the splice
site of IVS8 is associated with the variable efficiency of exon 9
splicing [14,48]. The (TG)m locus influences the penetrance of
the (T)5 allele, which may be associated with male infertility, in
particular in the context of (TG)12 and (TG)13 [15].
In the present study, the most common (TG)m-Tn Combina-
tions were TG11-T7 and TG12-T7 (the frequencies were 0.34Fig. 2. Schematic diagram showing putative dand 0.36), and the frequencies of TG10-T5, TG11-T5, TG11-
T9, TG12-T9 and TG13-T9 were 0 (Table 5).
The most common mutation, ΔF508, reaches frequencies of
about 70% in Northern European populations, while lower fre-
quencies are observed in our Chinese population. The muta-
tions in the CFTR gene are the most common cause of
CBAVD, but it also has other clinical presentations. Our
study of CFTR mutations in patients with CBAVD indicates
that CBAVD may be an extreme form of a wide nosologic
spectrum of conditions that have a common molecular basis.
These different patterns could share some of the same patho-
genic factors. Further studies with common diagnostic criteria
are required to confirm this hypothesis. It is also possible that
some causative mutations in our patients may lie outside the re-
gions analyzed in our study.
The results of this study reflect the high allelic heterogeneity
of CFTR gene mutations. In 64.4% of CBAVD patients, only
one or no CFTR mutation could be found. Unidentified CFTR
mutations may lie in regulatory regions of the introns, which
are not routinely investigated using current PCR-based tech-
niques, or may correspond to gene rearrangements such as
large deletions in the heterozygous state which escapeomain-type structure of the CFTR gene.
Table 5
Frequency of (TG)m-Tn Combination genotypes.
TG10 TG11 TG12 TG13 No information
T5 0 0 32(0.22) 4(0.03) 4
T7 1(0.01) 50(0.34) 52(0.36) 2(0.01) –
T9 1(0.01) 0 0 0 –
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using a semi-quantitative fluorescent PCR assay [49].
Although CBAVD patients are able to have children using
intracytoplasmic sperm injection (ICSI), they will experience
a higher risk than normal of having a child with CF. Assuming
a risk of 1/25 of the partner being a CF carrier, and the affected
male having a chance of 0.5 of transmitting the mutant CFTR
gene to the child, the combined risk of a CBAVD-affected cou-
ple having a CF child is 1/100. The partner of the CBAVD pa-
tients should be tested for CFTR mutations and clear genetic
counseling should be provided. Our findings provide new im-
portant information for predicting the risks of having a CF af-
fected child in China.
5. Conclusion
These findings also improve our understanding of the distri-
bution of CFTR alleles in Chinese CBAVD patients and will fa-
cilitate the development of more sensitive CFTR mutation
screening in the future.
Supplementary materials related to this article can be found
online at doi:10.1016/j.jcf.2012.01.005.
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